A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate
(Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected
children and babies. This study also examines how the body processes Rescriptor when taken
with 2 NRTIs.